摘要 |
The present disclosure relates to a pyridofuropyrimidine derivative of formula (I): wherein G<SUP>1 </SUP>is a group chosen from -CR<SUP>6</SUP>R<SUP>7</SUP>- and -O- wherein R<SUP>6 </SUP>and R<SUP>7 </SUP>are independently chosen from hydrogen atoms and C<SUB>1-4 </SUB>alkyl groups; R<SUP>1 </SUP>and R<SUP>2 </SUP>are independently chosen from hydrogen atoms and C<SUB>1-4 </SUB>alkyl groups; R<SUP>3 </SUP>is chosen from C<SUB>1-4 </SUB>alkyl, C<SUB>1-4 </SUB>alkoxy, amino, hydroxy, mono-C<SUB>1-4</SUB>alkylamino, di-C<SUB>1-4</SUB>alkylamino, C<SUB>3-8</SUB>cycloalkylamino, aryl, heteroaryl and saturated N-containing heterocyclyl groups which are bound to the pyridine ring through their nitrogen atom, all of them being optionally substituted by one or more substituents chosen from halogen atoms and hydroxy, C<SUB>1-4 </SUB>alkyl, C<SUB>1-4</SUB>alkoxy-C<SUB>1-4</SUB>alkyl, aryl-C<SUB>1-4</SUB>alkyl, -O(CO)OR<SUP>8</SUP>, C<SUB>1-4 </SUB>alkoxy, -(CO)NR<SUP>8</SUP>R<SUP>9</SUP>, -CN, -CF<SUB>3</SUB>, -NR<SUP>8</SUP>R<SUP>9</SUP>, -SR<SUP>8 </SUP>and -SO<SUB>2</SUB>NH<SUB>2 </SUB>groups wherein R<SUP>8 </SUP>and R<SUP>9 </SUP>are each independently chosen from a hydrogen atom or a C<SUB>1-4 </SUB>alkyl group; R<SUP>4 </SUP>and R<SUP>5 </SUP>are independently chosen from hydrogen atoms, C<SUB>1-4</SUB>alkyl groups, hydroxyl-C<SUB>1-4</SUB>alkyl groups and groups of formula (II): wherein p and q are integers chosen from 0, 1, 2 and 3; A is either a direct bond or a group chosen from -CONR<SUP>14</SUP>-, -NR<SUP>14</SUP>CO-, -O-, -COO-, -OCO-, -S-, -SO- and -SO<SUB>2</SUB>-, wherein each R<SUP>10</SUP>, R<SUP>11</SUP>, R<SUP>12</SUP>, R<SUP>13 </SUP>and R<SUP>14 </SUP>are independently chosen from a hydrogen atom and a C<SUB>1-4</SUB>alkyl group and G<SUP>2 </SUP>is chosen from aryl, heteroaryl and heterocyclyl groups; wherein the group G<SUP>2 </SUP>is optionally substituted by one or more substituents chosen from halogen atoms and C<SUB>1-4</SUB>alkyl, hydroxy, oxo, C<SUB>1-4</SUB>alkoxy-C<SUB>1-4</SUB>alkyl, aryl-C<SUB>1-4</SUB>alkyl, -(CO)OR<SUP>16</SUP>, C<SUB>1-4</SUB>alkoxy, -(CO)NR<SUP>16</SUP>R<SUP>17</SUP>, -CN, -CF<SUB>3</SUB>, -NR<SUP>16</SUP>R<SUP>17</SUP>-SR<SUP>16 </SUP>and -SO<SUB>2</SUB>NH<SUB>2 </SUB>groups; wherein R<SUP>16 </SUP>and R<SUP>17 </SUP>each independently chosen from hydrogen atom and a C<SUB>1-4</SUB>alkyl group and the pharmaceutically acceptable salts and N-oxides thereof. |